TY - JOUR
T1 - Hepatitis B virus infection in post-vaccination South Africa
T2 - Occult HBV infection and circulating surface gene variants
AU - Amponsah-Dacosta, Edina
AU - Lebelo, Ramokone L.
AU - Rakgole, J. Nare
AU - Selabe, Selokela G.
AU - Gededzha, Maemu P.
AU - Mayaphi, Simnikiwe H.
AU - Powell, Eleanor A.
AU - Blackard, Jason T.
AU - Mphahlele, M. Jeffrey
N1 - Publisher Copyright:
© 2014 Elsevier B.V.
PY - 2015/2/1
Y1 - 2015/2/1
N2 - Background and objective: The aim of this study was to investigate the prevalence of occult hepatitis B virus (HBV) infection and the HBV surface (S) gene variants circulating in the South African population after nearly two decades of universal hepatitis B vaccination. Study design: From a previous serosurvey, 201 serum samples with serological evidence of exposure to HBV were identified and these were stratified into post- and pre-vaccine introduction populations. For all samples, HBV DNA was screened and quantified using a real-time PCR assay and results analysed together with HBV serological markers. Where HIV results were available, subset analysis was performed. The HBV S gene was PCR-amplified and sequences analysed for a total of 37 isolates. Results: The prevalence of occult HBV infection reduced from 70.4% in the pre-vaccine introduction era to 66.0% post-vaccine introduction. There was an association between HIV infection and an increase in prevalence of occult HBV infection within the post-vaccine introduction population, although this was not statistically significant. Furthermore, sequence analysis revealed the following HBV subgenotypes; A1 (n= 34), A2 (n= 2) and a rare D4 isolate. HBV S gene variants, including diagnostic escape mutants were isolated. Conclusion: There was a decline in the prevalence of occult HBV infection in post-vaccination South Africa, although the disease burden remains significant in the HIV co-infected population. After nearly two decades of a universal hepatitis B vaccination programme, no positive selection of vaccine escape mutants were observed.
AB - Background and objective: The aim of this study was to investigate the prevalence of occult hepatitis B virus (HBV) infection and the HBV surface (S) gene variants circulating in the South African population after nearly two decades of universal hepatitis B vaccination. Study design: From a previous serosurvey, 201 serum samples with serological evidence of exposure to HBV were identified and these were stratified into post- and pre-vaccine introduction populations. For all samples, HBV DNA was screened and quantified using a real-time PCR assay and results analysed together with HBV serological markers. Where HIV results were available, subset analysis was performed. The HBV S gene was PCR-amplified and sequences analysed for a total of 37 isolates. Results: The prevalence of occult HBV infection reduced from 70.4% in the pre-vaccine introduction era to 66.0% post-vaccine introduction. There was an association between HIV infection and an increase in prevalence of occult HBV infection within the post-vaccine introduction population, although this was not statistically significant. Furthermore, sequence analysis revealed the following HBV subgenotypes; A1 (n= 34), A2 (n= 2) and a rare D4 isolate. HBV S gene variants, including diagnostic escape mutants were isolated. Conclusion: There was a decline in the prevalence of occult HBV infection in post-vaccination South Africa, although the disease burden remains significant in the HIV co-infected population. After nearly two decades of a universal hepatitis B vaccination programme, no positive selection of vaccine escape mutants were observed.
KW - Diagnostic escape mutants
KW - HIV infection
KW - Hepatitis B vaccine
KW - Occult HBV infection
KW - Subgenotype D4
UR - http://www.scopus.com/inward/record.url?scp=84921277024&partnerID=8YFLogxK
U2 - 10.1016/j.jcv.2014.11.032
DO - 10.1016/j.jcv.2014.11.032
M3 - Article
C2 - 25600597
AN - SCOPUS:84921277024
SN - 1386-6532
VL - 63
SP - 12
EP - 17
JO - Journal of Clinical Virology
JF - Journal of Clinical Virology
ER -